The anti-tumor activity of some antibodies, such as 264RAD and GC1008, has been proven; meanwhile, some small molecules that target TβR kinase, such as galunisertib, were also proven to be effective in hepato-cellular cancer and pancreatic cancer [124]; several TGF-β inhibitors have been evaluated in clinical trials. This evidence concerns the gene TGFB1 and neoplasm.